Supplementary Figure S2 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142956

2024-01-01

Abstract:Supplementary Figure S2. Tumor grown faster in cKO mice than Ncr1Cre/+ mice

What problem does this paper attempt to address?

Supplementary Figure S8 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142938

2024-01-01

Abstract:Supplementary Figure S8. NK-92 cells with FBXO38 overexpression show enhanced antitumor activity in vivo
Supplementary Figure S7 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142941

2024-01-01

Abstract:Supplementary Figure S7. FBXO38 promotes human NK-92 cell proliferation in vitro
Supplementary Figure S1 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142959

2024-01-01

Abstract:Supplementary Figure S1. Down regulation of FBXO38 in IT NK cells
Supplementary Figure S3 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142953

2024-01-01

Abstract:Supplementary Figure S3. FBXO38 knockout does not affect spleen NK cell development and effector function
Supplementary Figure S6 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142944

2024-01-01

Abstract:Supplementary Figure S6. FBXO38 deficiency increases the expression of suppressors of cell cycle program in TINK cells
Supplementary Figure S4 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142950

2024-01-01

Abstract:Supplementary Figure S4. FBXO38 does not affect NK cell trafficking
Supplementary Table 1 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142935

2024-01-01

Abstract:Supplemental Table 1. Antibodies used for flow cytometry in this study
Data from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.c.7474596

2024-01-01

Abstract:Abstract Natural killer (NK) cells are the main innate antitumor effector cells but their function is often constrained in the tumor microenvironment. It has been reported that the E3 ligase FBXO38 accelerates PD-1 degradation in tumor-infiltrating T cells to unleash their cytotoxic function. In this study, we found that the transcriptional levels of FBXO38 in intratumoral NK cells of patients with cancer and tumor-bearing mice were significantly lower than in peritumoral NK cells. Conditional knockout of FBXO38 in NK cells accelerated tumor growth and increased tumor metastasis. FBXO38 deficiency resulted in impaired proliferation and survival of tumor-infiltrating NK (TINK) cells. Mechanistically, FBXO38 deficiency enhanced TGF-β signaling, including elevating expression of Smad2 and Smad3, which suppressed expression of the transcription factor Eomes and further reduced expression of surface IL15Rβ and IL15Rγc on NK cells. Consequently, FBXO38 deficiency led to TINK cell hyporesponsiveness to IL15. Consistent with these observations, FBXO38 mRNA expression was positively correlated with the proliferation of TINK cells in multiple human tumors. To study the therapeutic potential of FBXO38, mice bearing human tumors were treated with FBXO38 overexpressed human primary NK cells and showed a significant reduction in tumor size and prolonged survival. In conclusion, our results suggest that FBXO38 sustains NK-cell expansion and survival to promote antitumor immunity and have potential therapeutic implications as they suggest FBXO38 could be harnessed to enhance NK cell–based cancer immunotherapy.
The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.CIR-23-1061

2024-10-01

Abstract:Natural killer (NK) cells are the main innate antitumor effector cells but their function is often constrained in the tumor microenvironment. It has been reported that the E3 ligase FBXO38 accelerates PD-1 degradation in tumor-infiltrating T cells to unleash their cytotoxic function. In this study, we found that the transcriptional levels of FBXO38 in intratumoral NK cells of patients with cancer and tumor-bearing mice were significantly lower than in peritumoral NK cells. Conditional knockout of FBXO38 in NK cells accelerated tumor growth and increased tumor metastasis. FBXO38 deficiency resulted in impaired proliferation and survival of tumor-infiltrating NK (TINK) cells. Mechanistically, FBXO38 deficiency enhanced TGF-β signaling, including elevating expression of Smad2 and Smad3, which suppressed expression of the transcription factor Eomes and further reduced expression of surface IL15Rβ and IL15Rγc on NK cells. Consequently, FBXO38 deficiency led to TINK cell hyporesponsiveness to IL15. Consistent with these observations, FBXO38 mRNA expression was positively correlated with the proliferation of TINK cells in multiple human tumors. To study the therapeutic potential of FBXO38, mice bearing human tumors were treated with FBXO38 overexpressed human primary NK cells and showed a significant reduction in tumor size and prolonged survival. In conclusion, our results suggest that FBXO38 sustains NK-cell expansion and survival to promote antitumor immunity and have potential therapeutic implications as they suggest FBXO38 could be harnessed to enhance NK cell-based cancer immunotherapy.
The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL-15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.cir-23-1061

IF: 10.1

2024-01-01

Cancer Immunology Research

Abstract:This study reveals that FBXO38 enhances NK cell-mediated antitumor immunity by maintaining IL15 signal strength. FBXO38 overexpressed human NK cells exert greater therapeutic efficacy in xenograft mouse models. Natural killer (NK) cells are the main innate antitumor effector cells but their function is often constrained in the tumor microenvironment. It has been reported that the E3 ligase FBXO38 accelerates PD-1 degradation in tumor-infiltrating T cells to unleash their cytotoxic function. In this study, we found that the transcriptional levels of FBXO38 in intratumoral NK cells of patients with cancer and tumor-bearing mice were significantly lower than in peritumoral NK cells. Conditional knockout of FBXO38 in NK cells accelerated tumor growth and increased tumor metastasis. FBXO38 deficiency resulted in impaired proliferation and survival of tumor-infiltrating NK (TINK) cells. Mechanistically, FBXO38 deficiency enhanced TGF-beta signaling, including elevating expression of Smad2 and Smad3, which suppressed expression of the transcription factor Eomes and further reduced expression of surface IL15R beta and IL15R gamma c on NK cells. Consequently, FBXO38 deficiency led to TINK cell hyporesponsiveness to IL15. Consistent with these observations, FBXO38 mRNA expression was positively correlated with the proliferation of TINK cells in multiple human tumors. To study the therapeutic potential of FBXO38, mice bearing human tumors were treated with FBXO38 overexpressed human primary NK cells and showed a significant reduction in tumor size and prolonged survival. In conclusion, our results suggest that FBXO38 sustains NK-cell expansion and survival to promote antitumor immunity and have potential therapeutic implications as they suggest FBXO38 could be harnessed to enhance NK cell-based cancer immunotherapy.
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494757.v1

2023-01-01

Abstract:EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494754

2023-01-01

Abstract:IL-6 modulates expression of NK receptor and their ligands in EGFR mutant tumors.
Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Ли Шен,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael A. Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22490453.v1

2023-01-01

Abstract:EGFR-mutant NSCLC tumor cells with acquired resistance to an EGFR-TKI display augmented IL-6 gene expression.
Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Xiaohui Fan,Randall J. Brezski,Hui Deng,Pooja Dhupkar,Yun Q. Shi,Anneliese Gonzalez,Songlin Zhang,Michael A. Rycyzyn,William R. Strohl,Robert E. Jordan,Ningyan Zhang,Zhiqiang An

DOI: https://doi.org/10.1158/1535-7163.22501711

2023-01-01

Abstract:Figure S1: IdeS expression in BT474 breast cancer cells Figure S2: Detection of MMPs in cancer cell lysates and culture supernatant Figure S3: scIgG-T was not in the SKBR-3 cell culture medium Figure S4: Detection of immune cells infiltration in mice by flow cytometry.
Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Zhiliang Ma,Wen Li,Shinichi Yoshiya,Yong Xu,Masaki Hara,Yosif El‐Darawish,Tzvetanka Markova,Kyosuke Yamanishi,Hiromichi Yamanishi,Hideaki Tahara,Yoshimasa Tanaka,Haruki Okamura

DOI: https://doi.org/10.1158/1078-0432.22459815.v1

2023-01-01

Abstract:Cytotoxic activity exhibited by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Figure S4 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419840

2023-01-01

Abstract:Supplementary figure S4. Immunofluorescence on intratumoral lymphocytes and qRT-PCR assays on TH1-type chemokine expression
Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22674261

2023-01-01

Abstract:Supplementary Fig. S9 shows enhanced IFNg and TNFa expression by T cells and NK cells in Rnf31/Atg5-dKO tumors.
Figure S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419843.v1

2023-01-01

Abstract:Supplementary figure S3. Flow cytometry analyses of tumor draining lymph nodes.
Supplementary Figure S8 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142117

2024-01-01

Abstract:Supplementary Figure S8. Bulk RNA-sequencing of tumor myeloid cells 7 days after RT and αEGFR-IFNα
Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22758761.v1

2023-01-01

Abstract:Supplementary Fig. S8 shows CD8 T cell-dependent control of tumors containing a B2m-/- population with inactivated Rnf31 and Atg5 genes.

Supplementary Figure S2 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S8 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S7 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S1 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S3 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S6 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S4 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Table 1 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Data from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL-15R Signaling

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Figure S4 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Figure S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure S8 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines